Nature Reviews Rheumatology

Article	Citations
Targeting KDM2/7 histone demethylases could protect against OA	499
Synthetic Wnt agonists rapidly rebuild bone in vivo	391
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	327
Annexin A1 could help prevent periprosthetic bone loss	306
Targeted NOD2 sequencing uncovers JIA misdiagnosis	259
Osteoarthritis risk factors differ between sexes	244
aPL target links coagulation and autoimmunity	237
Tapering csDMARDs leads to more RA flares	223
B cell X-chromosome inactivation is faulty in SLE	219
Polygenic risk scores outperform other tests in AS	207
Abatacept for myositis	203
SARS-CoV-2 vaccine safe for young patients	170
Genome-wide mutagenesis reported in systemic sclerosis	167
Stromal cells implicated in RA genetic risk	155
Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases	155
Imaging for prediction of RA development	153
Autoimmune disease increases CVD risk	147
Knee OA progression risk with steroids or HA	141
Are DNA–HLA class II interactions the missing link in SLE?	141
No benefit from adding MTX to ustekinumab	135
Bimekizumab effective across the axSpA spectrum	123
Iron uptake is a therapeutic target in SLE	120
Belimumab an option for Black patients with SLE	109
Inflammatory arthritis affects men’s fertility	101
Response to inflammation differs in gut and joint Treg cells	98

New treatments for amyloidosis	97
Optimizing methotrexate withdrawal during COVID vaccination	93
Cutaneous bacteria promote autoimmunity in mice	91
New OA risk factors and drug targets revealed	91
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	90
Low-dose rituximab can go even lower	90
Helicobacter pylori-induced citrullination linked to RA exacerbation	83
Pre-exposure prophylaxis reduces risk of COVID-19	83
CAR T cells induce remission in a patient with refractory SLE	83
FABP4 exacerbates RA	82
HLA autoimmunity risk alleles influence T cell receptor sequences	80
Risk variant regulates pDC hyperactivation in SLE	78
Targeting articular Mmp13 in OA	77
New guideline for integrative approaches to RA management	76
‘Hyalinization’ for cartilage regeneration	73
Carbamylated NETs promote bone erosion in RA	73
PJP prophylaxis with rituximab	72
BiTE therapy for rheumatic diseases	71
Non-depleting anti-CD19 B cell inhibition	71
Anti-inflammatory TNF receptor 2 signalling unravelled	70
Gut T cells help mediate fracture healing	67
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	66
BiTEing refractory RA	66
Wearable device for RA management?	66
Relapsing polychondritis: clinical updates and new differential diagnoses	65
Mitophagy as a link between ECM stiffness and chondrocyte senescence	65
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	61
Targeting senescence in OA	60
Critical appraisal of serum urate targets in the management of gout	59
Platelets promote cardiovascular complications in Kawasaki disease	58
Kindlin-2 reduces IVD inflammation	57
ZEB2 promotes formation of age-related B cells	56
Nanoparticle-based pazopanib shows promise in OA	56
Benralizumab noninferior to mepolizumab for EGPA	56
Advancing equity in genomic medicine for rheumatology	55
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	54
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	54
Discontinuing methotrexate to enhance vaccine response	53
Proposals for the rheumatological use of JAK inhibitors	53
The new look of classification criteria for systemic vasculitis	53
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	52
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	52
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	50
The emergence of SLE-causing UNC93B1 variants in 2024	48
Shifting the SLE management paradigm: challenges and implications	48
Exploring the latest advances in axial spondyloarthritis management	47
Insights into juvenile myositis via engineered muscle	46
The rise of precision cellular therapies	46
GCA management guidelines — vive la différence?	46
The past 25 years in paediatric rheumatology: insights from monogenic diseases	46

Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	45
Novel autoantigen in idiopathic lung disease	43
Lyme arthritis: linking infection, inflammation and autoimmunity	43
Engineering approaches for RNA-based and cell-based osteoarthritis therapies	42
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	40
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	40
Imaging inflammation with leukocyte-targeted PET tracers	40
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases	39
Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development	39
Epidemiology of the idiopathic inflammatory myopathies	38
Erosive hand osteoarthritis: latest findings and outlook	38
Emerging concepts of type I interferons in SLE pathogenesis and therapy	37
A role for TGFβ and EBV in MIS-C pathogenesis	36
High risk of autoimmune diseases after COVID-19	35
Stem and progenitor cells in the synovial joint as targets for regenerative therapy	34
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	34
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	33
Post-transcriptional checkpoints in autoimmunity	33
Precision medicine: the precision gap in rheumatic disease	33
25 years of biologic DMARDs in rheumatology	30
Rheumatic diseases on the rise	30
The role of neutrophils in rheumatic disease-associated vascular inflammation	29
Mechanisms and clinical implications of intervertebral disc calcification	29
Biological and clinical roles of IL-18 in inflammatory diseases	29
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce	29
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	28
Lupus nephritis-related chronic kidney disease	28
Which NSAIDs are best for OA treatment?	28
Bimekizumab safe and effective for AS and PsA in long-term trials	26
Defining axial involvement in juvenile SpA	25
Ferritin-induced NETs lead to cytokine storm in AOSD	25
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression	24
How muscle influences bone health	21
New biomarker panel best yet for prediction of OA progression	21
Anti-TNF dose can be reduced in PsA and axSpA	21
Use of platelet-rich plasma for knee OA not supported by RCT results	20
PLG nanoparticles target inflammatory monocytes in SSc	20
Collagen-binding antibody prevents arthritis	19
HLA-B27 linked to progression to axSpA in FDRs	19
Freeing PDL1 alleviates autoimmunity	19
Upadacitinib improves PsA in phase III trial	18
Tenascin C promotes pathological bone formation in AS	18
ETS1 implicated in polarization of tissue-destructive fibroblasts	17
New screening tool developed to aid diagnosis of axial PsA	17
Immune cell profiles stratify AOSD endotypes	17
Skin inflammation precedes lesions in cutaneous lupus erythematosus	16
Defibrotide inhibits NET-mediated thrombosis in APS models	15
Detachment promotes RA synovial fibroblast survival and invasiveness	15
FOXP3 splice variant is associated with autoimmune disease	15
Pregnancy outcomes in SLE have not improved	15
Mechanism of B cell survival in lupus nephritis	14
Nanohybrid therapy hits multiple arthritis targets	14
Articular cartilage hypoxia is a potential target for OA therapy	14
BRAVE news: another one bites the dust	13
New drug formulation reduces bone loss	13
Multi-omics reveals distinct MPA subtypes	13
Guselkumab effective through 2 years in PsA trial	13
IKKε promotes catabolic responses in OA	13
Arthritogenic peptide motif identified	13
COVID-19 linked to rise in anti-MDA5 autoimmunity	13
IL-37 has a protective role in IVD degeneration	13
Does psoriasis treatment affect PsA development?	13
Downregulation of invariant chain causes autoreactive T cell expansion	12
IRAK4 inhibitor attenuates inflammation	12
Adropin inhibits fibrosis in SSc	12
JAK inhibitors improve RA pain	12
Ageing stem cells hold the key to age-related bone degeneration	12
Aminoacyl-tRNA synthetases function as alarmins in RA	12
Topical NSAIDs come out top for knee OA	12
Evolving concepts in systemic lupus erythematosus damage assessment	11
SLE risk variant regulates IRF8 expression	11
Sarcoidosis: can tofacitinib slay the dragon?	10
Understanding synovial cell diversity in post-traumatic OA	10
Ikaros, Aiolos and other moving targets to treat SLE	10
2021 ACR guideline for JIA reflects changes in practice	10
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	10
The value of comparative efficacy studies in informing rheumatology guidelines	10
Complement therapeutics are coming of age in rheumatology	9
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	9
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions	9

To choose or not? The value of discrete-choice experiments in rheumatology	9
The 2022 ACR vaccination guideline: a call-to-action	9
Keep your Sox on, chondrocytes!	9
Maximizing the success of biosimilar implementation	8
Interferon lambda in inflammation and autoimmune rheumatic diseases	8
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	8
Regulation of activated T cell survival in rheumatic autoimmune diseases	8
COVID-19 vaccination in individuals with inflammatory rheumatic diseases	8
Somatic mutations in autoinflammatory and autoimmune disease	7
Dupuytren contracture treatments compared	7
Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases	7
Platelets in Kawasaki disease: mediators of vascular inflammation	7
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	7
Publisher Correction: Cardiovascular effects of approved drugs for rheumatoid arthritis	7
HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis	7
Limitations of the updated EULAR recommendations for osteoarthritis	6
Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies	6
Busting the myth of methotrexate chronic hepatotoxicity	6
Keeping immunostimulatory self-RNA under the rADAR	6
Virome associations in autoimmunity and COVID-19	6
Down syndrome: insights into autoimmune mechanisms	6
Appraising the evolving landscape of protease inhibition in osteoarthritis	6
European expert recommendations for managing systemic sclerosis and its complications	6
Revisiting the heterogeneity of interferon-related autoimmune diseases	6
Global epidemiology of vasculitis	5
Precision medicine in systemic lupus erythematosus	5
Emerging therapeutic options for refractory gout	5
The endothelium–bone axis in development, homeostasis and bone and joint disease	5
Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases	5
Cartilage calcification in osteoarthritis: mechanisms and clinical relevance	5
Recent advancements in cartilage tissue engineering innovation and translation	5
Towards better management of sterile bone inflammation	5
Acute exacerbation of interstitial lung disease associated with rheumatic disease	5
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	5
Notch signalling mediates OA pain in mice	5
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	5
Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging	4
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease	4
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	4
The role of mitochondria in rheumatic diseases	4
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus	4
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies	4
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	4
Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19	4
Z-DNA as an inflammatory trigger in lupus	4
State-of-the-art evidence in the treatment of systemic sclerosis	4
Urchin-like nanoparticles for miRNA therapy of OA	4
Granzyme serine proteases in inflammation and rheumatic diseases	4
Mechanisms and rationale for uricase use in patients with gout	4
Matrix metalloproteinases in arthritis: towards precision medicine	4
Obinutuzumab effective for lupus nephritis	4
MIS-C: myths have been debunked, but mysteries remain	4
Integrin signalling in joint development, homeostasis and osteoarthritis	4
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia	4
Immune mechanisms of depression in rheumatoid arthritis	4
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	3
Early-stage symptomatic osteoarthritis of the knee — time for action	3
Co-trimoxazole reduces mortality in anti-MDA5-DM	3
The decisive early phase of bone regeneration	3
Tofacitinib a promising oral therapy for JIA	3
Semaphorin 3G exacerbates joint inflammation	3
Vascular Behçet syndrome: from pathogenesis to treatment	3
Oral surveillance and JAK inhibitor safety: the theory of relativity	3
Cardio-rheumatology: it’s time to collaborate	3
Bone stresses out cartilage in OA	3
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	3
Benefits of sirtuin-6 in OA	3
Low-dose glucocorticoids benefit seniors with RA	3
Complement primes joints for inflammation	3
Placebo effects in osteoarthritis: implications for treatment and drug development	3
Epidemiology of Sjögren syndrome	3
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis	3
Inflammation across tissues: can shared cell biology help design smarter trials?	3
VEXAS syndrome more common than originally thought?	3
S100A4 inhibition targets fibrosis in SSc	3
Machine learning reveals antibody signature	3
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis	3
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management	3
TYK2: an emerging therapeutic target in rheumatic disease	2
GWAS expands list of Sjögren syndrome risk loci	2
Interosseous tendon inflammation associated with arthritis risk	2
Author Correction: Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells	2
The potential contribution of in silico studies to improved treatment of osteoarthritis	2
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need	2
NETs implicated in periodontitis-associated bone loss	2
Single-cell atlas unveils the diversity of RA synovial tissue	2
Passive smoking in childhood accelerates RA risk for smokers	2
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	2
Telemedicine: a solution for everyone?	2
Oral JAK inhibitor baricitinib effective in JIA	2
NEMO splice variant causes distinct autoinflammatory syndrome	2
Neutrophils implicated in early enthesitis	2
Linking autoimmunity, short telomeres and lung fibrosis in SSc	2
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	2
Assessment of disease outcome measures in systemic sclerosis	2